» Articles » PMID: 35003899

Landscape of Cancer-associated Fibroblasts Identifies the Secreted Biglycan As a Protumor and Immunosuppressive Factor in Triple-negative Breast Cancer

Overview
Journal Oncoimmunology
Date 2022 Jan 10
PMID 35003899
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer-associated fibroblasts (CAFs) are essential for tumor microenvironment remodeling and correlate with tumor progression. However, interactions between CAFs and tumor cells and immune cells in triple-negative breast cancer (TNBC) are still poorly explored. Here, we investigate the role of CAFs in TNBC and potential novel mediators of their functions. The clustering of classic markers was applied to estimate the relative abundance of CAFs in TNBC cohorts. Primary fibroblasts were isolated from normal and tumor samples. The RNA and culture medium of fibroblasts were subjected to RNA sequencing and mass spectrometry to explore the upregulated signatures in CAFs. Microdissection and single-cell RNA sequencing datasets were used to examine the expression profiles. CAFs were associated with hallmark signalings and immune components in TNBC. Clustering based on CAF markers in the literature revealed different CAF infiltration groups in TNBC: low, medium and high. Most of the cancer hallmark signaling pathways were enriched in the high CAF infiltration group. Furthermore, RNA sequencing and mass spectrometry identified biglycan (BGN), a soluble secreted protein, as upregulated in CAFs compared to normal cancer-adjacent fibroblasts (NAFs). The expression of biglycan was negatively correlated with CD8 + T cells. Biglycan indicated poor prognostic outcomes and might be correlated with the immunosuppressive tumor microenvironment (TME). In conclusion, CAFs play an essential role in tumor progression and the TME. We identified an extracellular protein, biglycan, as a prognostic marker and potential therapeutic target in TNBC.

Citing Articles

Tumor cell-derived EMP1 is essential for cancer-associated fibroblast infiltration in tumor microenvironment of triple-negative breast cancer.

Wang Q, Li D, Ma H, Li Z, Wu J, Qiao J Cell Death Dis. 2025; 16(1):143.

PMID: 40016223 PMC: 11868485. DOI: 10.1038/s41419-025-07464-9.


S100A13-driven interaction between pancreatic adenocarcinoma cells and cancer-associated fibroblasts promotes tumor progression through calcium signaling.

Xia L, Guo X, Lu D, Jiang Y, Liang X, Shen Y Cell Commun Signal. 2025; 23(1):51.

PMID: 39871271 PMC: 11773924. DOI: 10.1186/s12964-025-02049-7.


Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Serrano Garcia L, Javega B, Llombart Cussac A, Gion M, Perez-Garcia J, Cortes J Front Immunol. 2024; 15:1513421.

PMID: 39735530 PMC: 11671371. DOI: 10.3389/fimmu.2024.1513421.


Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells.

Khaliulin M, Valiullina A, Petukhov A, Yuan Y, Spada S, Bulatov E Cancer Immunol Immunother. 2024; 74(1):3.

PMID: 39487875 PMC: 11531461. DOI: 10.1007/s00262-024-03817-z.


Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer.

Haque M, Shyanti R, Mishra M Front Oncol. 2024; 14:1431418.

PMID: 39450256 PMC: 11499239. DOI: 10.3389/fonc.2024.1431418.


References
1.
Alcaraz L, Mallavialle A, David T, Derocq D, Delolme F, Dieryckx C . A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. Theranostics. 2021; 11(13):6173-6192. PMC: 8120228. DOI: 10.7150/thno.58254. View

2.
Hao Y, Hao S, Andersen-Nissen E, Mauck 3rd W, Zheng S, Butler A . Integrated analysis of multimodal single-cell data. Cell. 2021; 184(13):3573-3587.e29. PMC: 8238499. DOI: 10.1016/j.cell.2021.04.048. View

3.
Mai C, Kang Y, Pichika M . Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther. 2013; 6:1573-87. PMC: 3821792. DOI: 10.2147/OTT.S50838. View

4.
Jezequel P, Loussouarn D, Guerin-Charbonnel C, Campion L, Vanier A, Gouraud W . Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015; 17:43. PMC: 4389408. DOI: 10.1186/s13058-015-0550-y. View

5.
Karaayvaz M, Cristea S, Gillespie S, Patel A, Mylvaganam R, Luo C . Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018; 9(1):3588. PMC: 6123496. DOI: 10.1038/s41467-018-06052-0. View